Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.

@article{Home2007RosiglitazoneEF,
  title={Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.},
  author={Philip D Home and Stuart J. Pocock and Henning Beck-Nielsen and Ram{\'o}n Morell Gomis and Markolf Hanefeld and Nigel P. Jones and Michel Komajda and John J V McMurray},
  journal={The New England journal of medicine},
  year={2007},
  volume={357 1},
  pages={28-38}
}
BACKGROUND A recent meta-analysis raised concern regarding an increased risk of myocardial infarction and death from cardiovascular causes associated with rosiglitazone treatment of type 2 diabetes. METHODS We conducted an unplanned interim analysis of a randomized, multicenter, open-label, noninferiority trial involving 4447 patients with type 2 diabetes who had inadequate glycemic control while receiving metformin or sulfonylurea, in which 2220 patients were assigned to receive add-on… CONTINUE READING
Highly Influential
This paper has highly influenced 15 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
291 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 291 extracted citations

Similar Papers

Loading similar papers…